In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard ...

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that ...

This new meta-analysis looked to better solidify connections between atopic dermatitis and environmental irritants, such as ...

The decision by the Supreme Court has major implications on which preventive services are required to be covered by insurance companies under the Affordable Care Act.

Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving ...

Panelists emphasize that the approval of menin inhibitors has transformed the treatment landscape for KMT2A-rearranged acute ...